Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Another off shelf CAR-T had durability problems

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jul 11, 2023 11:09am

92 Views

Post# 35535418

RE:Another off shelf CAR-T had durability problems

" Promising early remission rates haven’t yet translated to the types of long-lasting benefits associated with CAR-T therapies, leading to lingering questions about their durability and effectiveness. "

Take note that this particular therapy is a CAR-NK cell therapy, and not
specifially CAR-T therapy.

"Nkarta believes the results with the newer regimen are “very meaningful” for AML patients with no other options, and “demonstrate the power” of natural killer, or NK cells, CEO Paul Hastings told BioPharma Dive."

Those findings have “clouded the entire allogeneic cell therapy space,” Hastings said, including developers of NK cell therapies."

https://www.biopharmadive.com/news/nkarta-acute-myeloid-leukemia-nk-cell-results/654083/

In June 2020 Caribuou Biosciences reported data from "off-the-shelf" therapy that added to the questions of durability, with three of six patients relapsing , one of whom saw their disease progress after three months, yet this month on July 06, 2023, Pfizer invested US$25 million into Caribou's allogeneic "off-the-shelf" CAR-T therapy

https://www.biopharmadive.com/news/caribou-biosciences-lymphoma-cell-therapy-results-eha/625280/

https://www.fiercebiotech.com/biotech/pfizer-pours-25m-equity-investment-caribous-cell-therapies

<< Previous

Bullboard Posts

Next >>

DRI Healthcare stock drops 28% after executive changes